DE60139553D1 - Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes - Google Patents

Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes

Info

Publication number
DE60139553D1
DE60139553D1 DE60139553T DE60139553T DE60139553D1 DE 60139553 D1 DE60139553 D1 DE 60139553D1 DE 60139553 T DE60139553 T DE 60139553T DE 60139553 T DE60139553 T DE 60139553T DE 60139553 D1 DE60139553 D1 DE 60139553D1
Authority
DE
Germany
Prior art keywords
diabetes
type
compositions
methods
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139553T
Other languages
English (en)
Inventor
Michael C Byrne
Andrew A Hill
Brian S Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Genetics Institute LLC
Original Assignee
General Hospital Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Genetics Institute LLC filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE60139553D1 publication Critical patent/DE60139553D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
DE60139553T 2000-06-05 2001-06-05 Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes Expired - Lifetime DE60139553D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20970300P 2000-06-05 2000-06-05
PCT/US2001/018418 WO2001094636A2 (en) 2000-06-05 2001-06-05 Compositions, kits, and methods for identification and modulation of type i diabetes

Publications (1)

Publication Number Publication Date
DE60139553D1 true DE60139553D1 (de) 2009-09-24

Family

ID=22779905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139553T Expired - Lifetime DE60139553D1 (de) 2000-06-05 2001-06-05 Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes

Country Status (9)

Country Link
US (2) US20020039736A1 (de)
EP (1) EP1290227B1 (de)
JP (1) JP2004510411A (de)
AT (1) ATE439453T1 (de)
AU (1) AU2001275346A1 (de)
CA (1) CA2411473A1 (de)
DE (1) DE60139553D1 (de)
ES (1) ES2331407T3 (de)
WO (1) WO2001094636A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
CA2485968A1 (en) * 2002-05-16 2004-06-03 Vanderbilt University Method for predicting autoimmune diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2527799A1 (en) * 2003-05-30 2004-12-16 Merck & Co., Inc. Methods for identifying modulators of kinesin activity
EP1538218A1 (de) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Verfahren zur Diagnose oder Untersuchung entzündlicher Krankheiten
EP1538219A1 (de) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Verfahren zur Diagnose oder Screening von Diabetes Mellitus Typ 1
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
JP2009511911A (ja) * 2005-10-11 2009-03-19 テシス バイオサイエンス， インコーポレイテッド 糖尿病関連マーカおよびその使用
WO2009015472A1 (en) * 2007-07-30 2009-02-05 London Health Sciences Centre Research Inc. Methods to diagnose type 1 diabetes by measuring cytokine and/or chemokine expression profiles.
ES2663662T3 (es) 2008-01-18 2018-04-16 President And Fellows Of Harvard College Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales
EP2419536A4 (de) * 2009-04-14 2012-09-05 Merck Sharp & Dohme Mikro-rna als biomarker für das eindringen von betazellen in die pankreasinseln
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806310A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
EP2965086A4 (de) 2013-03-09 2017-02-08 Harry Stylli Verfahren zum nachweis von prostatakrebs
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
CN116808063B (zh) * 2023-07-05 2023-12-12 中国医学科学院北京协和医院 糖尿病的标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE4209216A1 (de) 1992-03-21 1993-09-23 Boehringer Mannheim Gmbh Humaner t-zell-marker ht6
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
AU2087799A (en) 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells

Also Published As

Publication number Publication date
EP1290227A1 (de) 2003-03-12
JP2004510411A (ja) 2004-04-08
US20020039736A1 (en) 2002-04-04
WO2001094636A8 (en) 2002-01-10
WO2001094636A2 (en) 2001-12-13
US20050164233A1 (en) 2005-07-28
ATE439453T1 (de) 2009-08-15
CA2411473A1 (en) 2001-12-13
AU2001275346A1 (en) 2001-12-17
EP1290227B1 (de) 2009-08-12
ES2331407T3 (es) 2010-01-04

Similar Documents

Publication Publication Date Title
DE60139553D1 (de) Zusammensetzungen, testsätze und methoden zur identifizierung und modulation von typ i diabetes
DE60141950D1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
ATE272059T1 (de) Organische salze von isoleucyl-thiazolidin und - pyrrolidin und ihre verwendung als dipeptidylpeptidase-inhibitoren
BR0113161A (pt) Arilóxi piperidinas não imidazóis
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
DE60232323D1 (de) Verbessertes verfahren zum nachweis von atp
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
DE60140865D1 (de) Zusammensetzungen und methoden zur identifizierung von krebszellen
ATE468888T1 (de) Zusammensetzung zur färbung von keratinischen fasern enthaltend paraphenylendiamin-derivate mit einer pyrrolidinyl-gruppe
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
DE60138415D1 (de) Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände
ATE333522T1 (de) Verfahren zur bestimmung von mehrere analyten
ATE421090T1 (de) Neues screening-verfahren von modulatoren der bakteriellen transkription
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
ATE442161T1 (de) Botulinumneurotoxin-b-rezeptoren und ihreverwendung
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
ATE513814T1 (de) Acridane-9-dithiocarboxylatderivate zur erzeugung von chemolumineszenz mit einer peroxidase
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
ATE260467T1 (de) Reagens zur bestimmung der aptt
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata

Legal Events

Date Code Title Description
8364 No opposition during term of opposition